UroGen Pharma Ltd.'s (URGN) stock price soared 13.70% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results.

The biopharmaceutical company reported quarterly sales of $50.959 million, which exceeded analyst consensus estimates by 13.70%. Revenue surged 152% year-over-year, driven primarily by the successful commercial launch and broader adoption of ZUSDURI, supported by a permanent J Code that improved reimbursement starting in January 2026. The company's net loss also narrowed significantly, with a reported loss per share of $0.47, beating the estimated loss of $0.48.

Additional positive drivers included a 7% year-over-year increase in JELMYTO revenue, the reiteration of full-year 2026 guidance, and the company's plan to submit a New Drug Application for UGN-103 in the second half of the year, contributing to the strong positive investor sentiment.